Investigational/Trial Medications
Discuss investigational GLP-1 drugs: retatrutide, cagrilintide, tesofensine, survodutide, mazdutide, orforglipron. Trial results and research.
Retatrutide — the triple agonist. Phase 2/3 trial results, sourcing, testing, and comparison with tirzepatide.
Cagrilintide and CagriSema — dual therapy with semaglutide. Trial results, weight loss data, and sourcing discussion.
Tesofensine — the forgotten weight loss drug. Mechanism, trial results, sourcing, and user experiences.
Survodutide — dual GLP-1/glucagon agonist. Phase 3 results, MASH data, weight loss, and sourcing.
Mazdutide — China's GLP-1/glucagon agonist. Trial data, comparison with survodutide, and availability.
Orforglipron — the first oral non-peptide GLP-1. Trial results, dosing, and comparison with injectable GLP-1s.